Novartis to pay $1.5B for Myricx Bio and its novel ADC payloads

AI Briefing

• – Novartis to acquire Myricx Bio for $1.5 billion, expanding its ADC payload portfolio.
• – Myricx Bio's ADC payloads are designed to target cancer cells with improved efficacy and reduced toxicity.
• – Acquisition expected to enhance Novartis' oncology pipeline and expand its presence in the ADC market.